High Sensitivity Troponin (hsTnT) : Result Interpretation Matrix*

Slides:

Advertisements

Similar presentations

Local improvement following national clinical audit workshops Auditing heart attacks Saving lives Dr Andrew Wragg Barts Health.

Advertisements

Tobias Reichlin, W. Hochholzer, C. Stelzig, K. Laule, M. Potocki, K

High Sensitivity Troponin

British Cardiac Intervention Society Risk Assessment In Acute Coronary Syndromes Dr David Newby BHF Senior Lecturer in Cardiology Associate Director of.

Overly concerning and falsely reassuring?? FRAMINGHAM RISK FACTORS IN THE ED.

Acute Coronary Syndromes Clinical Care Standard An introduction for clinicians and health services.

Development of Clinical Pathways to Streamline Care for Patients Presenting with Suspected Cardiac Chest Pain Background The National Heart Foundation.

Sex-Specific Chest Pain Characteristics in AMI Jay Mansfield, Pgy-3 July 22, 2014 LSU Journal Club Gimenez, M, et. Al. Jama Int Med. 2014;174(2):

Please press F5 on your keyboard to enter presentation mode Welcome to the Eastern Health Pathology guide to hsTnT. The information in this presentation.

Primary Care Acute Chest Pain Awareness. Background BHF Funded Mid & South West Wales Project –Report from MINAP (Myocardial Ischaemia National Audit.

Ho PM, et al. JAMA 2009;301: Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:

ACUTE CORONARY SYNDORME Mostafa alshamiri January 2013.

“Challenging practice in non-ST segment elevation Acute Coronary Syndromes (ACS)” Professor Jennifer Adgey Royal Victoria Hospital, Belfast 26th January.

Absolute and Relative Kinetic Changes of High-Sensitivity Cardiac Troponin T in Acute Coronary Syndrome and in Patients with Increased Troponin in the.

©2012 National Heart Foundation of Australia Management of acute coronary syndromes (ACS) This presentation reflects the recommendations in the National.

Enzymes, Cardiac Markers, Hepatic Tests clinically useful enzymes: tissue sources preanalytical variables affecting enzyme activities isoenzymes myocardial.

Ischaemic Heart Disease CASE A. CASE A: Mr HA, aged 60 years, was brought in to A&E complaining of chest pain, nausea and a suspected AMI.

Implementation of a Sensitive Troponin I Assay and Risk of Recurrent Myocardial Infarction and Death in Patients With Suspected Acute Coronary Syndrome.

Cost Conscious Project: How Many Troponins Does It Take? Rola Khedraki.

Troponin By Julie Moore C Dt204/2.

Acute Coronary Syndrome

Women and Cardiovascular Disease

Figure 1 Initial management of a patient with acute heart failure

Arch Intern Med. 2007;167(1): doi: /archinte Figure Legend:

Consultant Clinical Scientist Royal Wolverhampton NHS Trust UK

Risk stratification in ACS F.Shakib .cardiologigst

CORONARY ARTERY DISEASE

Atypical chest pain, atypical perfusion CMR scan

Evaluation of Patients with chest pain Admitted under General Medicine; Has clinical judgment being taken over by serial troponins? Dr. Samantha Herath.

Tobias Reichlin, M. D. , Willibald Hochholzer, M. D

Survival probability (%)

Cost Effective Use of Troponin to Rule Out Acute Coronary Syndrome

Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology PET Measurements of Myocardial Blood flow Post Myocardial.

Improving Care Processes for Patients with Possible Acute Coronary Syndrome (ICARE-ACS)

Risk Factors for Rehospitalization for Acute Coronary Syndromes and Unplanned Revascularization Following Acute Myocardial Infarction by Suzanne V. Arnold,

Glenn N. Levine et al. JACC 2016;68:

Cardiac Troponin.

Cardiac Biomarkers.

STEMI-INITIAL PRESENTATION TIMING 2013 ACC/AHA GUIDELINES

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

بعض النقاط التي تؤخذ في الحسبان عند تقييم الاستثمارات الزراعية

Section A: Introduction

Nat. Rev. Cardiol. doi: /nrcardio

Advancing Acute Coronary Syndrome Assessment:

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

What oral antiplatelet therapy would you choose?

Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.

Correlation of change in H2 concentration (△H2) haemodynamics or laboratory parameters. Correlation of change in H2 concentration (△H2) haemodynamics or.

Forest plots of randomised controlled trials and propensity score matched studies examining outcomes between patients taking proton pump inhibitor (PPIs)

Algorithm for the investigation of patients with elevated cardiac troponin concentrations in the context of an alternative acute illness. Algorithm for.

Volume 70, Issue 3, Pages (August 2006)

Associations between atmospheric chemistry transport model pollution concentrations at lags 0, 1 and 2 and myocardial infarction (% change in risk per.

Jeffrey L. Anderson et al. JACC 2007;50:e1-e157

Illustration of a trial design to help evaluate the clinical accuracy of a test of ischaemia. Illustration of a trial design to help evaluate the clinical.

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

(Case 1) ST segment depression attributable to myocardial ischaemia (non-infarction)—ECG demonstrated NSR with ST segment depression in the anterolateral.

Decision tree (using the CHAID algorithm) for predicting participation in a cardiac prevention and rehabilitation programme (CPRP) among 420 Jewish and.

Result of coronary angiogram among patients with and without diabetes admitted with first-time acute coronary syndrome (a significant stenosis was defined.

Major bleeding with bivalirudin versus unfractionated heparin (UFH) in predominantly non-ST segment elevation acute coronary syndrome (NSTE-ACS) studies;

Javier Escaned et al. JCIN 2018;11:

Use of evidence-based cardiac medications before, during and after hospitalisation for the index event in (A) overall ACS population and (B) patients with.

Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

Performance of the Manchester Acute Coronary Syndromes decision rule with high-sensitivity cardiac troponin T (hs-cTnT) as the reference standard for the.

Performance of the Manchester Acute Coronary Syndromes decision rule in the validation study. Performance of the Manchester Acute Coronary Syndromes decision.

FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.

Traditional cardiovascular risk factors can cause cardiac disease in patients with IIM. Systemic and local inflammation may either have a direct effect.

Proposed future revascularisation strategy in patients with ESRD based on our current results and previous guideline recommendations. Proposed future revascularisation.

Study flow chart and diagnosis at discharge from ED

Cardioprotective effects of ivabradine administration in the setting of acute coronary syndromes and myocardial infarction. Cardioprotective effects of.

Presentation transcript:

High Sensitivity Troponin (hsTnT) : Result Interpretation Matrix* 1st hsTnT on presentation High Risk of Myocardial Ischaemia Low Risk of Myocardial Ischaemia  Clinical Assessment Result > 14 ? Result > 100 ? > 6 hrs of symptoms? 2nd hsTnT (taken at >6 hours post symptom onset AND >3 hours from 1st test) 1st or 2nd Result > 14 and > 50% change ? YES NO * this matrix is intended to assist with the interpretation of hsTnT results only - it does not represent a matrix for the clinical management of patients with chest pain Updated August 2011 in reference to “2011 Addendum to the National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand Guidelines for the Management of Acute Coronary Syndromes (ACS) 2006” Chew et al Heart. Lung and Circulation 2011 ; 20(8) : 487-502